About Eaglenos
Eaglenos is a company based in Nanjing (China) founded in 2017. Eaglenos has raised $21.2 million across 1 funding round from investors including 3E Bioventures, Huatai Zijin Investment and Innomed Capital. Eaglenos offers products and services including Test Paper Platform and Test Card Platform.
- Headquarter Nanjing, China
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 南京晶捷生物科技有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$21.2 M (USD)
in 1 rounds
-
Latest Funding Round
$21.2 M (USD), Series A
May 29, 2023
-
Investors
3E Bioventures
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eaglenos
Eaglenos offers a comprehensive portfolio of products and services, including Test Paper Platform and Test Card Platform.
Test paper platforms are used for precise detection in health management applications
Test card platforms are employed for point-of-care testing to support personalized health solutions
Funding Insights of Eaglenos
Eaglenos has successfully raised a total of $21.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $21.2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $21.2M
-
First Round
First Round
(29 May 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series A - Eaglenos | Valuation | 3E BioVentures |
Investors in Eaglenos
Eaglenos has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include 3E Bioventures, Huatai Zijin Investment and Innomed Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A fund focused on healthcare industry investments is managed.
|
Founded Year | Domain | Location | |
|
Innomed Capital is engaged in equity investment fund management.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed by the company.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eaglenos
Financial Statements - Eaglenos
Eaglenos Comparisons
Competitors of Eaglenos
Latest news on Eaglenos
Frequently Asked Questions about Eaglenos
Eaglenos was founded in 2017 and raised its 1st funding round 6 years after it was founded.
Eaglenos is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Eaglenos is a funded company, having raised a total of $21.2M across 1 funding round to date. The company's 1st funding round was a Series A of $21.2M, raised on May 29, 2023.
Eaglenos was established in 2017 in Nanjing, China, within the medical diagnostics sector. Diagnostic test kits are produced by the company to support healthcare testing needs. Operations are conducted from its base in Nanjing, where manufacturing processes are managed. The companys online presence is maintained through eaglenos.com, facilitating access to product information and distribution channels. Focus is placed on developing kits for various diagnostic purposes, serving regional and international markets.
Eaglenos offers Test Paper Platform and Test Card Platform.
Eaglenos has 4 investors. Key investors include 3E Bioventures, Huatai Zijin Investment, Innomed Capital, and Grand Yangtze.